

GP/1617

Docket No. PHUS-28

TECH CENTER 1600/2900

#7
JEL
9/17/01
RECEIVED
SEP 05 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Patent application of:
FAOUR, J. et al.Serial No.: 09/770,901
Filed: January 26, 2001For: Pharmaceutical compositions containing
A COX-II inhibitor and a muscle
relaxantAssistant Commissioner for Patents
Washington, D.C. 20231


Sir:

Group Art Unit: 1617
Examiner: Shaojia A. Jiang

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on August 27, 2001.

Rick Matos
Typed or printed name of person mailing paper


Signature of person mailing paper

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Office Action mailed August 14, 2001, Applicants hereby submit the following response.

REMARKS

Claims 1-39 remain pending herein. No claims have been amended and no new claims have been added. Reconsideration of the pending claims is requested.

Claims 1-39 stand subject to a restriction requirement 35 U.S.C. §121 as being related as product and process of use.

The claims have been divided as follows:

- Group 1: Claims 1-8 and 10-38
- Group 2: Claims 9 and 39.

Applicants hereby elect, with traverse, for further prosecution the subject matter of the claims of Group 1 and specifically a composition comprising rofecoxib and pridinol. Claims 1-8 and 10-38 are readable on the elected specie.

Applicants respectfully request entry of this Response into the record and full consideration thereof.

Respectfully submitted,



Rick Matos, Ph.D.
Registration No. 40,082
Agent for Applicant
Email: innovarllc@mindspring.com

Date: 8/27/01
Innovar, L.L.C.
P.O. Box 250647
Plano, TX 75025-0647
Ph.: 972-747-7373
Fax: 972-747-7375